Activation of estrogen receptor-α by the anion nitrite

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3950-3958

  Veselik, David J ^a   Divekar, Shailaja ^a   Dakshanamurthy, Sivanesan ^a   Storchan, Geoffrey B ^a   Turner, Jasmine M A ^a   Graham, Kelly L ^a   Huang, Li ^a   Stoica, Adriana ^a,b   Martin, Mary Beth ^a,b,c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANION; ANTIESTROGEN; ASPARAGINE; CATHEPSIN D; CYSTEINE; DIPHENYLIODONIUM SALT; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HISTIDINE; LYSINE; MESSENGER RNA; NITRATE; NITRITE; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GAL4; DRUG DERIVATIVE; ESR1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN MCF 7; CHIMERA; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIGAND BINDING; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; RECEPTOR UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; CONFORMATION; METABOLISM; TUMOR CELL LINE;

AMINO ACIDS; ANIMALS; ANIONS; CATHEPSIN D; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; MOLECULAR CONFORMATION; NITRITES; PROMOTER REGIONS (GENETICS); RECEPTORS, PROGESTERONE; TRANSFECTION;

EID: 45549090255     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2783     Document Type: Article

References (50)

1. Richie RC, Swanson JO. Breast cancer: a review of the literature. J Insur Med 2003;35:85-101.
2. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34: 405-12.
3. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-4.
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
5. Kampert JB, Whittemore AS, Paffenbarger RS, Jr. Combined effect of child-bearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol 1988;128:962-79.
6. MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. J Natl Cancer Inst 1973;50:21-42.
7. Steinberg KK, Thacker SB, Smith SJ. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
8. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-5.
9. Tokunaga M, Land CE, Yamamoto T, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res 1987; 112:243-72.
10. Dorgan JF, Baer DJ, Albert PS, et al. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 2001;93:710-5.
11. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 2003;77:171-83.
12. Colborn T, von Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993;101:378-84.
13. Safe S. Endocrine disruptors and human health: is there a problem? Toxicology 2004;205:3-10.
14. Garcia-Morales P, Saceda M, Kenney N, et al. Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem 1994;269:16896-901.
15. Stoica A, Katzenellenbogen BS, Martin MB. Activation of estrogen receptor-α by the heavy metal cadmium. Mol Endocrinol 2000;14:545-53.
16. Stoica A, Pentecost E, Martin MB. Effect of arsenite on estrogen receptor-a expression and activity in MCF-7 breast cancer cells. Endocrinology 2000;141: 3595-602.
17. Stoica A, Pentecost E, Martin MB. Effects of selenite on estrogen receptor-a expression and activity in MCF-7 breast cancer cells. J Cell Biochem 2000;79:282-92.
18. Martin MB, Reiter R, Pham T, et al. Estrogen like activity of metals in MCF-7 breast cancer cells. Endocrinology 2003;144:2425-36.
19. Shao W, Halachmi S, Brown M. ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol 2002;22:3358-72.
20. Webster NJ, Green S, Jin JR, Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcriptional activation function. Cell 1988;54:199-207.
21. Tora L, White J, Brou C, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989;59:477-87.
22. Reese JC, Katzenellenbogen BS. Mutagensis of cysteines in the hormone binding domain of the human estrogen receptor. J Biol Chem 1991;266:10880-7.
23. Pakdel F, Katzenellenbogen BS. Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 1992;267: 3429-37.
24. Wrenn CK, Katzenellenbogen BS. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem 1993;268: 24089-98.
25. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
26. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, Blake DR. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 1998;427:225-8.
27. WHO. Guidelines for drinking water quality. Health criteria and other supporting information. 2nd ed. Geneva: WHO; 1998.
28. Nitrification occurrence and control in chloraminated water systems. Denver (CO): American Water Works Association Research Foundation; 1995.
29. WHO. Evaluation of certain food additives and contaminants Geneva: World Health Organization, Joint FAO/WHO Expert Committee on Food Additives WHO Technical Report Series No.859, 1995.
30. ECETOC. Nitrate and drinking water Brussels: European Chemical Industry Ecology and Toxicology Centre Technical Report No. 27, 1988.
31. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35:790-6.
32. Hirokawa T, Yoshioka M, Okamoto H, Timerbaev AR, Blaschke G. High-sensitivity capillary electrophoresis determination of inorganic anions in serum and urine using on-line preconcentration by transient isotachophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:165-70.
33. Hwang J, Mack WJ, Xiang M, Sevanian A, Lobo RA, Hodis HN. Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT). Atherosclerosis 2005;181:375-80.
34. Mansoor MA, Kristensen O, Hervig T, et al. Relationship between serum folate and plasma nitrate concentrations: possible clinical implications. Clin Chem 2005;51:1266-8.
35. Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast cancer patients. Cancer 2002;95:663-7.
36. Gonenc A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 2006;30:376-80.
37. Reveneau S, Arnould L, Jolimoy G, et al. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 1999;79:1215-25.
38. Jadeski LC, Charkraborty C, Lala PK. Nitric oxide mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen activated protein kinase. Int J Cancer 2003;106:496-504.
39. Jang TJ, Kim DK. Inducible nitric oxide synthase expression to tumor and stromal cells is associated with the progression of 7,12-dimetylbenz(a) anthracene induced rat mammary tumors. Cancer Lett 2003;182: 121-6.
40. Ellies LG, Fishman M, Hardison J, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003;106:1-7.
41. Gardner KM, Ou SX, Jin F, et al. Occupations and breast cancer risk among Chinese women in urban Shanghai. Am J Ind Med 2002;42:296-308.
42. Band PR, Le ND, Fang R, Deschamps M, Gallagher RP, Yang P. Identification of occupational cancer risks in British Columbia. A population-based case-control study of 995 incident breast cancer cases by menopausal status, controlling for confounding factors. J Occup Environ Med 2000;42: 284-310.
43. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998;13:1755-9.
44. Nelson RJ, Demas GE, Huang PL, et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995;378:383-6.
45. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995;375: 377-82.
46. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 1997;389:753-8.
47. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domain. Proc Natl Acad Sci U S A 1998;95:5998-6003.
48. Egea PF, Mitschler A, Rochel N, Ruff M, Chambon P, Moras D. Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J 2000;19:2592-601.
49. Wurtz JM, Bourguet W, Renaud JP, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996;3:87-94.
50. Egea PF, Klaholz BP, Moras D. Ligand-protein interactions in nuclear receptors of hormones. FEBS Lett 2000;476:62-7.